Cerebellar Ataxia Clinical Trials 2023

Cerebellar Ataxia Clinical Trials 2023

Cerebellar Ataxia research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in cerebellar ataxia clinical trials today.

Trials for Friedreich Ataxia Patients

Trials for FA Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to cerebellar ataxia

What are the top hospitals conducting cerebellar ataxia research?

In the realm of cerebellar ataxia, several top hospitals are leading the charge in clinical trials and groundbreaking research. The University of South Florida in Tampa is taking a prominent role with six active trials focused on this condition, along with an impressive total of 18 previous studies. Since their first recorded cerebellar ataxia trial back in 2009, this institution has been dedicated to advancing our understanding and treatment options for individuals affected by this neurological disorder.

On the West Coast, UCLA in Los Angeles is also making significant strides in the fight against cerebellar ataxia. With four ongoing trials and six completed studies since initiating their first trial in 2015, UCLA's commitment to exploring innovative approaches to tackle this condition is evident.

Further east, Johns Hopkins University School of Medicine located in Baltimore may have only two active cerebellar ataxia trials currently underway but they are contributing to vital research efforts. Interestingly enough, they conducted their very first trial on cerebellar ataxia as recently as 2022 – a testament to how rapidly medical progress can be achieved.

Meanwhile Northwestern University in Chicago joins forces with two current clinical investigations targeting cerebellar ataxia while sharing similar historical significance: conducting its pioneering study regarding these disorders commencing from2016.The University of Chicago also based within Chi-town landscape adds up significantly through it's present-day dedication housing two active tests for cerabellum irregularity; furthermore contributing towards various experiments summing upto four that paved way over last decade starting from capturing initial associated case into account during preliminary investigation beginning from years ago lasting until2010

These esteemed institutions showcase not just their expertise but also unwavering commitment toward improving the lives of individuals afflicted by cerebellar ataxia. By pushing boundaries and seeking breakthroughs through clinical trials across different locations including Tampa Bay ,Los Angeles,Baltimore,and Chicago - researchers strive tirelessly towards finding effective treatments and ultimately a cure for this debilitating neurological condition.

Which are the best cities for cerebellar ataxia clinical trials?

When it comes to cerebellar ataxia clinical trials, several cities offer promising opportunities for research and treatment development. Los Angeles, California stands out with 8 active trials focusing on IB1001, troriluzole, and other potential interventions. New york, New York follows closely behind with 7 ongoing studies exploring aerobic training, troriluzole, and more. Tampa, Florida also shows promise with 7 active trials investigating troriluzole and IVIG among other treatments. Philadelphia, Pennsylvania contributes to the advancement of care through 7 studies involving vatiquinone and omaveloxolone capsules. Finally, Boston Massachusetts offers 5 active trials studying troriluzole and SLS-005 in an effort to improve outcomes for individuals with cerebellar ataxia.

Which are the top treatments for cerebellar ataxia being explored in clinical trials?

Exciting developments are underway in the exploration of treatments for cerebellar ataxia. Leading the charge is vatiquinone, currently involved in two active trials and three all-time cerebellar ataxia trials since its listing in 2020. Another promising avenue being explored is transcranial magnetic stimulation (TMS), with one active trial and two all-time cerebellar ataxia trials recorded since 2016. Additionally, aerobic training shows potential as a treatment option, with one ongoing trial among its two all-time cerebellar ataxia trials listed from 2020 onwards. These innovative approaches offer hope to those affected by this challenging neurological condition.

What are the most recent clinical trials for cerebellar ataxia?

Recent clinical trials offer new hope for individuals with cerebellar ataxia, a debilitating condition affecting coordination and movement. Among these trials is the exploration of vatiquinone as a potential treatment, which has progressed to Phase 3 after showing promising results in earlier phases. Additionally, CTI-160l and SLS-005 are being investigated in Phase 2 and Phase 3 studies respectively, aiming to assess their effectiveness in managing cerebellar ataxia symptoms. Another promising avenue is the use of high-dose LX2006, currently undergoing combined Phase 1 and Phase 2 testing. As these trials continue to advance our understanding of this complex disorder, we move closer towards finding effective therapies that can improve the quality of life for those affected by cerebellar ataxia.

What cerebellar ataxia clinical trials were recently completed?

In the realm of cerebellar ataxia, a notable clinical trial recently concluded, shedding light on potential advancements in treatment. Design Therapeutics sponsored a trial investigating DT-216 and successfully completed it in March 2022. This study's completion signals progress towards tackling the challenges associated with cerebellar ataxia, offering hope for improved therapies for individuals affected by this debilitating condition.